PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hmgLink to Publisher's site
 
Hum Mol Genet. Oct 15, 2011; 20(R2): R132–R141.
Published online Aug 9, 2011. doi:  10.1093/hmg/ddr349
PMCID: PMC3179383
Direct-to-consumer personalized genomic testing
Cinnamon S. Bloss,1 Burcu F. Darst,1 Eric J. Topol,1,2,3* and Nicholas J. Schork1,2*
1Scripps Genomic Medicine, Scripps Health, Scripps Translational Science Institute, Ja Jolla, CA, USA,
2Department of Molecular and Experimental Medicine, The Scripps Research Institute, Ja Jolla, CA, USA, and
3Scripps Clinic Medical Group, Ja Jolla, CA, USA
*To whom correspondence should be addressed at: Scripps Translational Science Institute, 3344 N. Torrey Pines Court, Suite 300, La Jolla, CA 92037, USA. Tel: +1 8585545709 Fax: +1 8585469284; Email: nschork/at/scripps.edu (N.J.S.) or Scripps Translational Science Institute, 3344 N. Torrey Pines Court, Suite 300, La Jolla, California 92037, USA. Tel: +1 8585545707; Fax: +1 8585469272; Email: etopol/at/scripps.edu (E.J.T.)
Received July 21, 2011; Accepted August 4, 2011.
Over the past 18 months, there have been notable developments in the direct-to-consumer (DTC) genomic testing arena, in particular with regard to issues surrounding governmental regulation in the USA. While commentaries continue to proliferate on this topic, actual empirical research remains relatively scant. In terms of DTC genomic testing for disease susceptibility, most of the research has centered on uptake, perceptions and attitudes toward testing among health care professionals and consumers. Only a few available studies have examined actual behavioral response among consumers, and we are not aware of any studies that have examined response to DTC genetic testing for ancestry or for drug response. We propose that further research in this area is desperately needed, despite challenges in designing appropriate studies given the rapid pace at which the field is evolving. Ultimately, DTC genomic testing for common markers and conditions is only a precursor to the eventual cost-effectiveness and wide availability of whole genome sequencing of individuals, although it remains unclear whether DTC genomic information will still be attainable. Either way, however, current knowledge needs to be extended and enhanced with respect to the delivery, impact and use of increasingly accurate and comprehensive individualized genomic data.
Over the past few years, there has been a flurry of activity in the direct-to-consumer (DTC) genetic testing space, an area of genomics that has been fraught with controversy. As the number of companies and number of tests offered by each company have proliferated (1), so, too, have efforts aimed at increased governmental regulation of this industry, especially in the USA (2,3). Over the past year, we have also seen actual empirical data start to emerge on both perceptions of and attitudes toward DTC genetic testing, as well as on psychological and behavioral responses to testing. Our review of available studies suggests, however, that more work in this area is desperately needed even though there are challenges with respect to the design and timely execution of such studies. For instance, there are no available studies on long-term follow-up of individuals who have undergone DTC genomic testing for disease susceptibility, nor any studies on response to testing for genetic ancestry or pharmacogenomic testing. Further, there are still open questions with respect to the consistency of disease risk estimates provided by different DTC companies (4,5), as well as related questions surrounding the clinical validity and clinical utility of tests that are offered.
In this review, we briefly discuss the pros and cons of DTC personalized genomic testing and describe the current landscape of the DTC genetic testing market. We also review important events over the past year, which have been aimed at issues surrounding US governmental regulation of DTC testing. We then delineate ongoing large-scale research initiatives that aim to inform relevant issues pertaining to DTC genomic testing, as well as currently available research findings in this area. Finally, we comment on topics that we believe are ‘on the horizon’ in this area, including DTC genomic testing of children and adolescents, as well as the potential for affordable DTC whole genome sequencing (WGS). We suggest that DTC genomic testing for common markers and conditions is only a precursor to the eventual cost-effectiveness and wide availability of WGS of individuals, although whether or not this information will remain directly available to consumers is still an open question.
As of May 2010, there were >30 DTC genetic testing companies that collectively offered >400 health-related tests (1), and these numbers appear to be on the rise. These tests can, by definition, be purchased by consumers online. The fees for different tests have typically ranged from $99 to over $2000, and testing does not require the involvement of a health-care provider, although some companies are now imposing such a requirement [e.g. pathway genomics (6)]. There are a range of types of genetic tests that are currently offered DTC, as well as wide variation with respect to the extent to which each company uses the scientific literature to support their decisions concerning which tests they offer. This review will, for the most part, focus on tests where results are provided for multiple common genetic markers conferring susceptibilities for multiple common health conditions and traits. These tests are based on high-throughput genome-wide genotyping technologies and findings from genome-wide association studies (7). Starting in late 2007, a number of companies began offering such testing, including 23andMe (8), Navigenics (9), deCODE (10) and in 2008, Pathway Genomics (6).
This type of testing has been highly controversial. Those opposed to it argue that it has limited value given the small relative risks contributed by common genetic variants and the fact that most variants identified to date only account for a small fraction of the genetic variance of any one disease. There is also evidence that the risk estimates provided across companies are inconsistent (4,5,11,12), primarily due to the use of different single nucleotide polymorphisms (SNPs) and risk prediction algorithms. For the most part, the various tests offered also currently lack demonstrated clinical validity and utility (13,14). Other criticisms are that consumers may be confused by their results, or experience anxiety related to premature estimates of high risk, which could result in the pursuit of expensive and unnecessary medical interventions (15). Alternatively, they may be falsely reassured by estimates of low risk and fail to take appropriate preventative measures. On this point, several professional organizations (1618), including the National Society of Genetic Counselors (19), American College of Medical Genetics (20) and American Medical Association (AMA) (21), have put forth position statements indicating that genetic testing should involve a health-care provider. Other concerns include the possibility of discrimination if privacy is not maintained and the exacerbation of existing health disparities related to the costs of testing and inequitable access for different groups of individuals.
On the other hand, proponents of DTC genomic testing argue that there is public interest in genomic information and that it is overly paternalistic to deny individuals access to information about their own bodies. It is also proposed that direct access to genomic testing may empower consumers to educate themselves, as well as to make proactive decisions about their own health, such as decisions to engage in lifestyle behavioral change efforts aimed at disease risk reduction. In this regard, genomic information is thought by some to be inherently more powerful relative to other types of non-genetic risk information, a notion commonly referred to as ‘genetic exceptionalism’ (22). Some also assert that DTC genetic testing may, somewhat counter-intuitively, be a viable alternative for individuals who are fearful of genetic discrimination and insurance loss resulting from testing through a health-care provider with the results documented in medical records (23). Overall, these factors have prompted countless commentaries on these and other related topics including, but not limited to, the risks and need (or not) for regulation of DTC testing (2433), the impact of DTC testing on consumers (3437), physicians and the healthcare system (15,38), the appropriateness and impact of disease-specific testing (3941) and implications for genomic research (4244).
While there has been a lively debate over these issues since the above-mentioned DTC genomic testing companies came on the scene roughly 4 years ago, over the past 18 months, issues around US governmental regulation have come to a head (Table 1, timeline). Specifically, consumer genomic testing came under fire in May 2010 when Pathway Genomics announced a partnership with Walgreens Drug Stores in which they planned to sell their DNA saliva kits on the shelves at >6000 retail stores nationwide (45). This would have marked the first time that the sale of these tests moved from internet commerce to retail availability. This led the US Food and Drug Administration (FDA) to question the federal regulatory approval of the tests offered by all of the primary DTC genomic testing companies (6,810,46) and another service provider (47).
Table 1.
Table 1.
Recent timeline of DTC genetic testing events
In part prompted by these events, the FDA held a public meeting in July 2010 to help determine how regulation of so-called laboratory developed tests (LDTs) should proceed. That same month there was a Congressional Committee hearing to evaluate the ‘public health consequences’ of DTC genomic testing (48), as well as the release of a new report assembled by the General Accounting Office (GAO) in which a ‘sting’ operation targeted at DTC genomic testing companies was unveiled (5). The report presented findings, which suggested that some of the companies not only produced inaccurate test results, but also engaged in deceptive marketing practices. Notably, this was not the first such report on DTC testing issued by the GAO (49). Discussion regarding regulation continued when, in February 2011, the AMA sent a letter to the FDA strongly suggesting that all genetic testing be pursued under the guidance of a physician (21), which some have suggested is ironic given that most physicians report a lack of knowledge in the area of genomic medicine (50,51). This was done in advance of a March meeting where a special panel was convened to gather information on, and to evaluate the benefits and harms of, DTC genomic testing in order to inform the FDA (3). While, to our knowledge, no firm decisions have been made yet regarding the regulatory process for DTC genomic testing, the sense among many is that soon such tests may only be available through one's physician.
In parallel, the National Institutes of Health (NIH) has responded to increasing concerns over the need for transparency about genetic testing and the potential for misinterpretation of results by initiating the development of a Genetic Testing Registry (GTR) (52). The GTR will be a publically available, online database that provides information addressing the availability, clinical validity and clinical utility of genetic tests. The goal of this effort is to better equip physicians and consumers to determine the appropriateness of specific genetic tests (53). Information in the registry will be voluntarily provided by genetic testing companies, and it is projected to become available in late 2011.
The controversies around DTC genomic testing have been complicated by a lack of empirical, prospective data. To begin to bridge this gap, we know of three large-scale research studies that have been initiated, including the Coriell Personalized Medicine Collaborative (CPMC) (54,55), the Multiplex Initiative (5658) and an effort from our own institute, the Scripps Genomic Health Initiative (SGHI) (59,60). While all three studies are unique in several respects, they share a notable strength, which is the enrollment of large sample sizes. Previous studies on the behavioral and psychological response to testing for single-gene conditions have been limited in this respect (61). We briefly describe each of these initiatives below, and then in the following section, review specific research findings that have emerged from these efforts, in addition to other published studies.
Coriell Personalized Medicine Collaborative
The CPMC (54) is a prospective observational cohort study designed to assess the impact of multiplex genomic testing and return-of-results on health behaviors. A recent paper by Keller and colleagues (55) indicated that over 4000 individuals have been enrolled in the CPMC community cohort to date. Participants provide medical history information via a web-based survey, and DNA is tested for at least 16 health conditions. Participants receive an email request to complete a follow-up health behavior outcome survey every 3 and 12 months after viewing a risk report. Thus far, customized risk results (55) have been disclosed for a subset of six conditions; however, there are currently no published data of which we are aware that have reported on the behavioral response of individuals to testing.
Multiplex Initiative
The Multiplex Initiative was launched in 2006 and is led by scientists at the National Human Genome Research Institute (NHGRI) (56). This initiative is also a prospective, observational study, and is designed to answer questions about the characteristics of individuals who, when offered free susceptibility testing for multiple common diseases, have interest in being tested (62). Particular strengths of this study are that participants were drawn from a known sampling frame of individuals enrolled in a large health system and health maintenance organization, and groups traditionally under-represented in research were over-sampled. The genetic test offered includes 15 genetic variants that confer risk for eight common health conditions (63). Published reports to date indicate that the total number of individuals who completed an initial survey and considered undergoing testing was 612, which was 14% of the surveyed sample; of these, 266 provided written consent and had blood drawn for testing (64). The behavioral responses of those participants who underwent testing are assessed via a 3-month follow-up telephone survey. Although we are not aware of any published reports on response to testing, there have been a number of reports that have evaluated characteristics associated with interest in multiplex testing and the decision to get tested (57).
Scripps Genomic Health Initiative
The SGHI is also a prospective, longitudinal, cohort study designed to assess response to DTC genomic testing. The study was initiated in October 2008. Over 4000 individuals were enrolled in the study (59), and roughly half completed an initial follow-up assessment administered at 3 months post-testing (60). Although similar in some respects to the previous two initiatives, the SGHI possesses some unique features, including the fact that SGHI participants purchased a commercially available DTC genomic test [the Navigenics HealthCompass (9)]. Thus, in many ways, participants can be thought of as reflecting ‘real’ consumers of DTC genomic testing, and indeed, characterization of the sample has revealed that it is largely representative of the current population of consumers of DTC genomic tests (60). Therefore, of all of these initiatives, the SGHI would seem to most closely mirror the current realities of how DTC genomic tests are currently being offered to the public. In the SGHI, participants were administered baseline, as well as 3- and 12-month follow-up web-based health assessments focusing on surveillance/health screening behaviors, lifestyle (i.e. diet and exercise) and psychological functioning. Reports on both the baseline characteristics and perceptions of the sample (59), as well as on the response of participants to testing (60) have been published.
It is worth mentioning that other initiatives, while not focused on multiplex genetic testing, have helped to inform some research questions related to DTC genomic testing and return of genetic susceptibility risk estimates. One notable example is the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study in which adult children of individuals with Alzheimer's disease (AD) are offered testing for the apolipoprotein epsilon 4 (APOE-epsilon4) genotype, which confers susceptibility to AD. This study has shown minimal psychological impact of testing (65), and some preliminary evidence of moderate behavioral impact (66). Smaller scale studies on the clinical (67) as well as behavioral impact (58,68,69) of genetic testing for common susceptibility variants have also been done. Furthermore, a search of the NIH's database of currently funded projects (70) using the search term direct-to-consumer reveals 17 matches, including study topics ranging from attitudes and experiences of early adopters of personalized genomics to the impact of DTC genetic testing on policy development. This suggests that additional research to inform this controversial area of genomics may soon start to emerge.
We searched the empirical and qualitative research literatures for studies that pertain to, or were designed to inform, DTC genomic testing. Our search produced a few noteworthy findings. First, in general, although many commentaries have been published on this topic, there are few actual research studies (Table 2). Secondly, very few studies have been published to date that address what is a primary issue in DTC genomic testing, which is how consumers interpret, understand and respond to test results. In fact, a published report from our own SGHI study is the only study of which we are aware that has addressed this question in a large cohort (60). Findings from this study indicated minimal impacts of testing on participants, including a lack of psychological harm. The other main finding was that respondents reported the intention to undergo specific clinical screening tests with greater frequency, which correlated with the pattern of disease risk results that were disclosed. With the exception of two published case studies of individuals who underwent DTC genomic testing (23,71), we found only one other study that has evaluated response to multiplex genomic testing, which was a small-sample study of individuals with advanced training in genetics (72) (Table 2).
Table 2.
Table 2.
Recent empirical and qualitative research informing multiplex DTC genomic testing for common disease
The other studies identified seem to reflect a few main themes, including (i) awareness of DTC genomic testing; (ii) demographics, interest and attitudes and perceptions among potential consumers and health-care providers; (iii) communication of genomic information and genomic risk; and (iv) the impact of testing on the health-care system. In terms of public awareness, findings to date seem to suggest that while some segments of the population (e.g. well-educated, internet-savvy individuals) are quite aware of DTC genomic tests, the majority of the general population is not (7376). Consistent with this, one study published in 2010 estimated that the overall demand for DTC genomic tests at the time of the study was likely small, and thus the impact on health systems was likely to also be minimal (77). Likewise, two studies that have actually tried to assess the impact of DTC genomic testing on the number of health-care referrals have also drawn similar conclusions (78,79). Importantly, all of these studies only reflect the landscape of DTC genomic testing at a given point in time and cannot necessarily speak to future demand.
In terms of uptake of testing by different groups, early studies suggest that women, individuals of Caucasian background, and highly educated individuals are most likely to undergo testing (54,59,62). Further, those interested in testing primarily cite curiosity as the reason (51,80,81) or a belief that it is important to learn about genetics (57). They also often indicate their intention to include their physician in the process (80,82). Also, interestingly, even those who decide or intend to undergo testing still have concerns about the process, most notably concerns related to confidentiality (51,59). A few other studies have also examined communication patterns around delivery of DTC genomic test results. This work suggests that individuals can find web-based information on multiplex genomic testing to be helpful in their decision-making around whether or not to be tested (83); however, a content analysis of 29 actual DTC websites found that overall, the sites demanded high literacy levels, suggesting that many users may struggle to find and understand important information (84).
Two other prominent types of tests offered by many DTC genomic testing companies are pharmacogenomic tests and testing for ancestry or one's ‘geographical origins’. Pharmacogenomic markers and associations arguably represent an area of genomics that may in fact be most ready for clinical translation (85), although as with DTC genomic disease susceptibility testing, ethical and social issues have been raised (86,87). Table 3 shows pharmacogenomic tests offered as of June 2011 by the three primary DTC genomic testing companies. In regards to ancestry testing, Royal et al. (88) indicated that at the time of publication, there were ~40 companies in various countries that were providing genetic ancestry testing to the public. Although there are population-specific differences in disease and drug response (89) and thus ancestry testing could theoretically inform health-related issues, it has been suggested that most scientists and consumers view these tests as merely recreational (90). Notably, we know of no studies that have evaluated consumer response to either pharmacogenomic or ancestry testing. Questions such as whether or not consumers bring their ‘medications’ test results to their physician, or whether ancestry testing is impactful in terms of an individual's self-concept, loom large. In the future, we hope to be able to speak to such questions through analysis of relevant data we have collected as part of our SGHI study. Further, several companies are continually developing new tests, including tests that take into account an individual's specific phenotypic characteristics (e.g. see the ‘Pathway Fit’ test, a nutrigenomic test currently offered by Pathway Genomics: https://www.pathway.com/dna-reports/pathway-fit).
Table 3.
Table 3.
Pharmacogenomic tests offered by three primary DTC genomic testing companies as of June 2011
An interesting outgrowth of commercial DTC genomic testing is that some companies offering such testing are, in parallel, building their own databases and conducting genetic research on the basis of the data obtained from their customers (44). 23andMe (8) is likely the most prominent example of a company operating in this way, and from the time they opened their doors, they have embraced a business model that has clearly reflected the intention to promote and perform research (91). This model of ‘crowdsourcing’ genetic disease research (43,92) in many ways stands in opposition to conventional models and thus has been an additional source of controversy with respect to DTC genomic testing (93). In 2010, researchers affiliated with 23andMe published the first report to emerge from what they termed their ‘web-based, participant-driven’ genetic studies (94) in which they identified new genetic trait associations, as well as replicated several previously reported findings. Their second study, focused on the genetic basis of Parkinson's disease, was published in 2011, identified two novel loci and represented a meaningful contribution to the field (95). The success of these studies as well as other similar initiatives [e.g. for ancestry, the National Geographic ‘Genographic’ project (96)] suggests that this model of research participation, powered by large sample sizes that are hard to come by but a necessity for genomic research, may be both fruitful in terms of genetic discovery, as well as less costly compared with more traditional research mechanisms.
Since the emergence of the first DTC genomic testing companies in 2007, this area of genomics has been evolving rapidly and has been the subject of much intense debate. Anecdotally, at least, there is evidence that public interest in genomics appears to be increasing [e.g. the availability of personal genomics mobile ‘apps’ such as DYI Genomics (92) and the Genome Wowser (97), the popularity of genomics websites such as www.snpedia.com]. Therefore, it is likely that the important issues raised with respect to the public's level of access to genomic testing will remain a priority area for current and future research.
We concur with others in the field regarding the need for further and ongoing thoughtful evaluation of the potential harms to consumers associated with DTC genomic testing (98). Although we offer that our initial analysis of this issue in the context of our SGHI study suggests that adverse anxiety reactions, at least, may be minimal (60), additional studies are needed. However, given this preliminary evidence coupled with similar findings from studies of risk-disclosure for single-gene conditions (61), we would urge policy makers to proceed cautiously in any effort to limit the ability of consumers to access this information. While some level of regulation is likely appropriate, over-regulating may serve to stifle innovation in this burgeoning area of scientific translation (99).
In terms of future work, we propose that there are a few particularly relevant areas of DTC genomic testing that would greatly benefit from further research. These include, but are not limited to, the following: (i) research on consumer response to both DTC pharmacogenomic testing, as well as ancestry testing; (ii) issues surrounding the need for physician education in the area of genomic medicine (50,51,100), as well as studies on the best and most efficient ways of presenting individual-level genomic data to health-care providers; (iii) the possible DTC testing of minors (101), especially given evidence that younger individuals may be most amenable to adopting or changing risk-reducing lifestyle habits (102) and that parents may find testing to be beneficial (103) (Table 3); (iv) the need for research on the potential development of effective preventative lifestyle behavioral interventions that leverage genomic information and ‘feedback loops’ (104); (v) research to better elucidate how genomic discoveries and information can be combined with other emerging health-related technologies, such as wireless sensors, to improve patient care and disease prevention (105); and (vi) finally, issues related to study design in the context of DTC research that has been pursued to date, including the limits associated with certain designs (e.g. studies that lack a control group) and alternative designs for testing certain hypotheses. While we propose these as important avenues of inquiry in this space, we also note the difficulties associated with pursuing research in this area. Specifically, the rapid pace at which the field (in particular the technology) is evolving poses challenges in terms of designing (as well as obtaining funding for) studies that will, once completed, produce findings relevant to the behavioral and psychosocial milieu of DTC genomic testing at that future point in time.
Ultimately, the era of genome-wide scanning can be considered only a segue to WGS. This is especially true as the costs for the latter have been ratcheting down at a rate far beyond projections, although we note that cost is not the primary bottleneck to delivery of personalized genomic information. One company that offers WGS to ‘private clients’ recently announced provision of their services for research purposes for <$5000 per genome (106). There has also been media coverage of high-profile celebrities obtaining such testing (107), as well as emerging evidence that sequencing strategies for medical purposes is reaping early rewards in terms of the diagnosis and effective treatment of rare diseases (108110).
In terms of direct access to genomic testing for consumers, we believe that the ‘democratization of DNA’ that has already been initiated is important to preserve. Individuals and patients should have a right to have their DNA analyzed if they can be assured that this is being done with the highest level of accuracy and with defined limits regarding how the data can be interpreted. In particular, the notion that individuals would be better off if genomic testing were only available through a physician seems flawed given the well-documented lack of physician education and knowledge in genomics (50). Notwithstanding these points, it remains unclear whether or not genomic information (whether it be SNP- or sequence-based) will remain available to consumers without the involvement of a health-care provider. Either way, however, current knowledge needs to be extended and enhanced with respect to the delivery, impact and use of increasingly accurate and comprehensive individualized genomic data.
Conflict of Interest statement. None declared.
FUNDING
This work was supported in part by a National Institutes of Health/National Human Genome Research Institute R21 grant (grant number 1R21HG005747-01 to C.S.B.), a National Institutes of Health/National Center for Research Resources flagship Clinical and Translational Science Award grant (grant number 1UL1RR025774-01 to E.J.T.) and Scripps Genomic Medicine Division of Scripps Health.
1. DTC Genetic Testing Companies. The Genetics and Public Policy Center. 2010. (cited 20 June 2011). Available from http://www.dnapolicy.org/resources/AlphabetizedDTCGeneticTestingCompanies.pdf .
2. Pollack A. F.D.A. Faults Companies on Unapproved Genetic Tests. New York: The New York Times; 2010.
3. Summary from the Molecular & Clinical Genetics Panel Meeting—March 8 and 9, 2011. Department of Health & Human Services; 2011. (cited 1 July 2011). Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/UCM246907.pdf .
4. Ng P.C., Murray S.S., Levy S., Venter J.C. An agenda for personalized medicine. Nature. 2009;461:724–726. doi:10.1038/461724a. [PubMed]
5. Kutz G.D. United States Government Accountability Office; 2010. DIRECT-TO-CONSUMER GENETIC TESTS: misleading test results are further complicated by deceptive marketing and other questionable practices. (cited 05 July 2011). Available from http://www.gao.gov/new.items/d10847t.pdf .
6. Pathway Genomics. (cited 1 July 2011); Available from http://www.pathway.com/
7. Manolio T.A., Brooks L.D., Collins F.S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 2008;118:1590–1605. doi:10.1172/JCI34772. [PMC free article] [PubMed]
8. 23andMe. (cited 1 July 2011). Available from https://www.23andme.com/
9. Navigenics. (cited 1 July 2011). Available from http://www.navigenics.com/
10. deCODEME. (cited 4 March 2011). Available from http://www.decodeme.com/
11. Swan M. Multigenic condition risk assessment in direct-to-consumer genomic services. Genet. Med. 2010;12:279–288. doi:10.1097/GIM.0b013e3181d5f73b. [PubMed]
12. Imai K., Kricka L.J., Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin. Chem. 2011;57:518–521. doi:10.1373/clinchem.2010.158220. [PubMed]
13. Burke W. Clinical validity and clinical utility of genetic tests. Curr. Protoc. Hum. Genet. 2009 Chapter 9, Unit 9 15. [PubMed]
14. Eng C., Sharp R.R. Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing: the problem of misattributed equivalence. Sci. Transl. Med. 2010;2 17cm15. [PubMed]
15. McGuire A.L., Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA. 2008;300:2669–2671. doi:10.1001/jama.2008.803. [PMC free article] [PubMed]
16. Direct-to-Consumer Marketing of Genetic Testing. ACOG Committee Opinion No. 409. Obstet. Gynecol. 2008;111:1493–1494. doi:10.1097/AOG.0b013e31817d250e. [PubMed]
17. Hudson K., Javitt G., Burke W., Byers P. ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet. Gynecol. 2007;110:1392–1395. doi:10.1097/01.AOG.0000292086.98514.8b. [PubMed]
18. Ameer B., Krivoy N. Direct-to-consumer/patient advertising of genetic testing: a position statement of the American College of Clinical Pharmacology. J. Clin. Pharmacol. 2009;49:886–888. doi:10.1177/0091270009335948. [PubMed]
19. National Society of Genetic Counselors: Position Statements. (cited 6 July 2011). Available from http://www.nsgc.org/Media/PositionStatements/tabid/330/Default.aspx#DTC .
20. ACMG Statement on Direct-to-Consumer Genetic Testing. American College of Medical Genetics; 2008. (cited 6 July 2011). Available from http://www.acmg.net/StaticContent/StaticPages/DTC_Statement.pdf . [PubMed]
21. Maves M.D. AMA Letter to Division of Dockets Management (HFA-305) Food and Drug Administration; 2011.
22. Green M.J., Botkin J.R. “Genetic exceptionalism” in medicine: clarifying the differences between genetic and nongenetic tests. Ann. Intern. Med. 2003;138:571–575. [PubMed]
23. Roberts M.E., Riegert-Johnson D.L., Thomas B.C. Self diagnosis of lynch syndrome using direct to consumer genetic testing: a case study. J. Genet. Couns. 2011;20:327–329. doi:10.1007/s10897-011-9356-y. [PubMed]
24. Annes J.P., Giovanni M.A., Murray M.F. Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med. 2010;363:1100–1101. doi:10.1056/NEJMp1006029. [PubMed]
25. Beaudet A.L. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature. 2010;466:816–817. doi:10.1038/466816a. [PubMed]
26. Caulfield T. Direct-to-consumer testing: if consumers are not anxious, why are policymakers? Hum. Genet. 2011;130:23–25. doi:10.1007/s00439-011-0987-8. [PubMed]
27. Gurwitz D., Bregman-Eschet Y. Personal genomics services: whose genomes? Eur. J. Hum. Genet. 2009;17:883–889. doi:10.1038/ejhg.2008.254. [PMC free article] [PubMed]
28. Hogarth S., Javitt G., Melzer D. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu. Rev. Genomics Hum. Genet. 2008;9:161–182. doi:10.1146/annurev.genom.9.081307.164319. [PubMed]
29. Javitt G. Which way for genetic-test regulation? Assign regulation appropriate to the level of risk. Nature. 2010;466:817–818. doi:10.1038/466817a. [PubMed]
30. Kaye J. The regulation of direct-to-consumer genetic tests. Hum. Mol. Genet. 2008;17:R180–R183. doi:10.1093/hmg/ddn253. [PMC free article] [PubMed]
31. Magnus D., Cho M.K., Cook-Deegan R. Direct-to-consumer genetic tests: beyond medical regulation? Genome Med. 2009;1:17. doi:10.1186/gm17. [PMC free article] [PubMed]
32. McGuire A.L., Evans B.J., Caulfield T., Burke W. Science and regulation. Regulating direct-to-consumer personal genome testing. Science. 2010;330:181–182. doi:10.1126/science.1194006. [PubMed]
33. Wright C.F., Hall A., Zimmern R.L. Regulating direct-to-consumer genetic tests: what is all the fuss about? Genet. Med. 2011;13:295–300. doi:10.1097/GIM.0b013e3181f69dd2. [PubMed]
34. Evans J.P., Meslin E.M., Marteau T.M., Caulfield T. Genomics. Deflating the genomic bubble. Science. 2011;331:861–862. doi:10.1126/science.1198039. [PubMed]
35. Evans J.P., Dale D.C., Fomous C. Preparing for a consumer-driven genomic age. N. Engl. J. Med. 2010;363:1099–1103. doi:10.1056/NEJMp1006202. [PubMed]
36. Hunter D.J., Khoury M.J., Drazen J.M. Letting the genome out of the bottle—will we get our wish? N. Engl. J. Med. 2008;358:105–107. doi:10.1056/NEJMp0708162. [PubMed]
37. Ransohoff D.F., Khoury M.J. Personal genomics: information can be harmful. Eur. J. Clin. Invest. 2010;40:64–68. doi:10.1111/j.1365-2362.2009.02232.x. [PubMed]
38. McGuire A.L., Burke W. Health system implications of direct-to-consumer personal genome testing. Public Health Genomics. 2011;14:53–58. doi:10.1159/000321962. [PMC free article] [PubMed]
39. Janssens A.C., Gwinn M., Bradley L.A., Oostra B.A., van Duijn C.M., Khoury M.J. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am. J. Hum. Genet. 2008;82:593–599. doi:10.1016/j.ajhg.2007.12.020. [PubMed]
40. Janssens A.C., Wilde A.A., van Langen I.M. The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease. Neth. Heart. J. 2011;19:85–88. doi:10.1007/s12471-010-0069-x. [PMC free article] [PubMed]
41. Lovett K.M., Liang B.A. Direct-to-consumer cardiac screening and suspect risk evaluation. JAMA. 2011;305:2567–2568. doi:10.1001/jama.2011.865. [PubMed]
42. Howard H.C., Knoppers B.M., Borry P. Blurring lines. The research activities of direct-to-consumer genetic testing companies raise questions about consumers as research subjects. EMBO Rep. 2010;11:579–582. doi:10.1038/embor.2010.105. [PubMed]
43. Prainsack B. Voting with their mice: personal genome testing and the "participatory turn" in disease research. Account Res. 2011;18:132–147. [PubMed]
44. Tutton R., Prainsack B. Enterprising or altruistic selves? Making up research subjects in genetics research. Sociol. Health Illn. 2011 DOI:10.1111/j.1467-9566.2011.01348.x. [PubMed]
45. Pollack A. Start-up May Sell Genetic Tests in Stores. New York: The New York Times; 2010. May 10.
46. Knome. (cited 2 July 2011). Available from http://www.knome.com/
47. Illumina. (cited 2 July 2011). Available from http://www.illumina.com/
48. Madrigal A. Congress Opens Investigation Into Genetic Testing Companies. Wired; 2010.
49. Kutz G.D. NUTRIGENETIC TESTING: Tests Purchased from Four Web Sites Mislead Consumers. United States Government Accountability Office; 2006. (cited 5 July 2011). Available from http://www.gao.gov/new.items/d06977t.pdf .
50. Healy M. October 24. As genetic testing races ahead, doctors are left behind. Los Angeles: Los Angeles Times; 2009.
51. Ormond K.E., Hudgins L., Ladd J.M., Magnus D.M., Greely H.T., Cho M.K. Medical and graduate students’ attitudes toward personal genomics. Genet. Med. 2011;13:400–408. doi:10.1097/GIM.0b013e31820562f6. [PubMed]
52. Genetic Testing Registry. (cited 2 July 2011). Available from http://www.ncbi.nlm.nih.gov/gtr/
53. Kuehn B.M. NIH launching genetic test registry. JAMA. 2010;303:1685. doi:10.1001/jama.2010.493. [PubMed]
54. Keller M.A., Gordon E.S., Gharani N., Sill C.J., Schmidlen T.J., Mintzer J., Pallies J., Gerry N.P., Christman M.F. Coriell personalized medicine collaborative: a prospective study of the utility of personalized medicine. Personalized Med. 2010;7:301–317. doi:10.2217/pme.10.13.
55. Stack C.B., Gharani N., Gordon E.S., Schmidlen T., Christman M.F., Keller M.A. Genetic risk estimation in the Coriell Personalized Medicine Collaborative. Genet. Med. 2011;13:131–139. doi:10.1097/GIM.0b013e318201164c. [PubMed]
56. McBride C.M., Alford S.H., Reid R.J., Larson E.B., Baxevanis A.D., Brody L.C. Putting science over supposition in the arena of personalized genomics. Nat. Genet. 2008;40:939–942. doi:10.1038/ng0808-939. [PMC free article] [PubMed]
57. McBride C.M., Alford S.H., Reid R.J., Larson E.B., Baxevanis A.D., Brody L.C. Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions. Genet. Med. 2009;11:582–587. doi:10.1097/GIM.0b013e3181b22c3a. [PMC free article] [PubMed]
58. McBride C.M., Koehly L.M., Sanderson S.C., Kaphingst K.A. The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu. Rev. Public Health. 2010;31:89–103. doi:10.1146/annurev.publhealth.012809.103532. [PubMed]
59. Bloss C.S., Ornowski L., Silver E., Cargill M., Vanier V., Schork N.J., Topol E.J. Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet. Med. 2010;12:556–566. doi:10.1097/GIM.0b013e3181eb51c6. [PubMed]
60. Bloss C.S., Schork N.J., Topol E.J. Effect of direct-to-consumer genomewide profiling to assess disease risk. N. Engl. J. Med. 2011;364:524–534. doi:10.1056/NEJMoa1011893. [PMC free article] [PubMed]
61. Heshka J.T., Palleschi C., Howley H., Wilson B., Wells P.S. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet. Med. 2008;10:19–32. doi:10.1097/GIM.0b013e31815f524f. [PubMed]
62. Hensley Alford S., McBride C.M., Reid R.J., Larson E.B., Baxevanis A.D., Brody L.C. Participation in genetic testing research varies by social group. Public Health Genomics. 2010;14:85–93. doi:10.1159/000294277. [PMC free article] [PubMed]
63. Wade C.H., McBride C.M., Kardia S.L., Brody L.C. Considerations for designing a prototype genetic test for use in translational research. Public Health Genomics. 2010;13:155–165. doi:10.1159/000236061. [PMC free article] [PubMed]
64. McBride C.M., Wade C.H., Kaphingst K.A. Consumers’ views of direct-to-consumer genetic information. Annu. Rev. Genomics Hum. Genet. 2010;11:427–446. doi:10.1146/annurev-genom-082509-141604. [PubMed]
65. Green R.C., Roberts J.S., Cupples L.A., Relkin N.R., Whitehouse P.J., Brown T., Eckert S.L., Butson M., Sadovnick A.D., Quaid K.A., et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 2009;361:245–254. doi:10.1056/NEJMoa0809578. [PMC free article] [PubMed]
66. Vernarelli J.A., Roberts J.S., Hiraki S., Chen C.A., Cupples L.A., Green R.C. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am. J. Clin. Nutr. 2010;91:1402–1407. doi:10.3945/ajcn.2009.28981. [PubMed]
67. Scheuner M.T., Sieverding P., Shekelle P.G. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA. 2008;299:1320–1334. doi:10.1001/jama.299.11.1320. [PubMed]
68. Marteau T.M., French D.P., Griffin S.J., Prevost A.T., Sutton S., Watkinson C., Attwood S., Hollands G.J. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst. Rev. 2010:CD007275. DOI:10.1002/14651858.CD007275.pub2. [PubMed]
69. McBride C.M., Bepler G., Lipkus I.M., Lyna P., Samsa G., Albright J., Datta S., Rimer B.K. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol. Biomarkers Prev. 2002;11:521–528. [PubMed]
70. NIH Research Portfolio Online Reporting Tools (RePORT) (cited 4 July 2011). Available from http://projectreporter.nih.gov/reporter.cfm .
71. Austin S.E., Hegele R.A. Clinical implications of direct-to-consumer genetic testing for cardiovascular disease risk. Can. J. Cardiol. 2011 DOI:10.1016/j.cjca.2011.02.006. [PubMed]
72. O'Daniel J.M., Haga S.B., Willard H.F. Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals. J. Genet. Couns. 2010;19:387–401. doi:10.1007/s10897-010-9297-x. [PubMed]
73. Bowen D.J., Harris J., Jorgensen C.M., Myers M.F., Kuniyuki A. Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign. Public Health Genomics. 2010;13:131–142. doi:10.1159/000231722. [PubMed]
74. Kolor K., Liu T., St Pierre J., Khoury M.J. Health care provider and consumer awareness, perceptions, and use of direct-to-consumer personal genomic tests, United States, 2008. Genet. Med. 2009;11:595. doi:10.1097/GIM.0b013e3181b1cc2c. [PubMed]
75. McGuire A.L., Diaz C.M., Wang T., Hilsenbeck S.G. Social networkers’ attitudes toward direct-to-consumer personal genome testing. Am. J. Bioeth. 2009;9:3–10. [PMC free article] [PubMed]
76. Goddard K.A., Duquette D., Zlot A., Johnson J., Annis-Emeott A., Lee P.W., Bland M.P., Edwards K.L., Oehlke K., Giles R.T., et al. Public awareness and use of direct-to-consumer genetic tests: results from 3 state population-based surveys, 2006. Am. J. Public Health. 2009;99:442–445. doi:10.2105/AJPH.2007.131631. [PubMed]
77. Wright C.F., Gregory-Jones S. Size of the direct-to-consumer genomic testing market. Genet. Med. 2010;12:594. doi:10.1097/GIM.0b013e3181ead743. [PubMed]
78. Hock K.T., Christensen K.D., Yashar B.M., Roberts J.S., Gollust S.E., Uhlmann W.R. Direct-to-consumer genetic testing: an assessment of genetic counselors’ knowledge and beliefs. Genet. Med. 2011;13:325–332. doi:10.1097/GIM.0b013e3182011636. [PMC free article] [PubMed]
79. Giovanni M.A., Fickie M.R., Lehmann L.S., Green R.C., Meckley L.M., Veenstra D., Murray M.F. Health-care referrals from direct-to-consumer genetic testing. Genet. Test Mol. Biomarkers. 2010;14:817–819. doi:10.1089/gtmb.2010.0051. [PMC free article] [PubMed]
80. Gollust S.E., Gordon E.S., Zayac C., Griffin G., Christman M.F., Pyeritz R.E., Wawak L., Bernhardt B.A. Motivations and perceptions of early adopters of personalized genomics: perspectives from research participants. Public Health Genomics. 2011 DOI:10.1159/000327296. [PMC free article] [PubMed]
81. Su Y., Howard H.C., Borry P. Users’ motivations to purchase direct-to-consumer genome-wide testing: An exploratory study of personal stories. J. Community Genet. 2011 DOI:10.1007/s12687–011-0048-y. [PMC free article] [PubMed]
82. Wilde A., Meiser B., Mitchell P.B., Hadzi-Pavlovic D., Schofield P.R. Community interest in predictive genetic testing for susceptibility to major depressive disorder in a large national sample. Psychol. Med. 2011;41:1605–1613. doi:10.1017/S0033291710002394. [PubMed]
83. Kaphingst K.A., McBride C.M., Wade C., Alford S.H., Brody L.C., Baxevanis A.D. Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. J. Med. Internet Res. 2010;12:e41. [PMC free article] [PubMed]
84. Lachance C.R., Erby L.A., Ford B.M., Allen V.C., Jr., Kaphingst K.A. Informational content, literacy demands, and usability of websites offering health-related genetic tests directly to consumers. Genet. Med. 2010;12:304–312. doi:10.1097/GIM.0b013e3181dbd8b2. [PMC free article] [PubMed]
85. Bloss C.S., Jeste D.V., Schork N.J. Genomics for disease treatment and prevention. Psychiatr. Clin. North Am. 2011;34:147–166. doi:10.1016/j.psc.2010.11.005. [PMC free article] [PubMed]
86. Katsanis S.H., Javitt G., Hudson K. Public health. A case study of personalized medicine. Science. 2008;320:53–54. doi:10.1126/science.1156604. [PubMed]
87. Vijverberg S.J., Pieters T., Cornel M.C. Ethical and social issues in pharmacogenomics testing. Curr. Pharm. Des. 2010;16:245–252. doi:10.2174/138161210790112700. [PubMed]
88. Royal C.D., Novembre J., Fullerton S.M., Goldstein D.B., Long J.C., Bamshad M.J., Clark A.G. Inferring genetic ancestry: opportunities, challenges, and implications. Am. J. Hum. Genet. 2010;86:661–673. doi:10.1016/j.ajhg.2010.03.011. [PubMed]
89. Via M., Ziv E., Burchard E.G. Recent advances of genetic ancestry testing in biomedical research and direct to consumer testing. Clin. Genet. 2009;76:225–235. doi:10.1111/j.1399-0004.2009.01263.x. [PMC free article] [PubMed]
90. Bolnick D.A., Fullwiley D., Duster T., Cooper R.S., Fujimura J.H., Kahn J., Kaufman J.S., Marks J., Morning A., Nelson A., et al. Genetics. The science and business of genetic ancestry testing. Science. 2007;318:399–400. doi:10.1126/science.1150098. [PubMed]
91. Avey L. Introducing a Do-It-Yourself Revolution in Disease Research. 2009. (cited 6 July 2011). Available from http://spittoon.23andme.com/2009/07/07/introducing-a-do-it-yourself-revolution-in-disease-research/
92. DIYgenomics. (cited 1 July 2011). Available from http://www.diygenomics.org/
93. Zawati M.H., Borry P., Howard H.C. Closure of population biobanks and direct-to-consumer genetic testing companies. Hum. Genet. 2011 DOI:10.1007/s00439–011-1019-4. [PubMed]
94. Eriksson N., Macpherson J.M., Tung J.Y., Hon L.S., Naughton B., Saxonov S., Avey L., Wojcicki A., Pe'er I., Mountain J. Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 2010;6:e1000993. doi:10.1371/journal.pgen.1000993. [PMC free article] [PubMed]
95. Do C.B., Tung J.Y., Dorfman E., Kiefer A.K., Drabant E.M., Francke U., Mountain J.L., Goldman S.M., Tanner C.M., Langston J.W., et al. Web-Based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011;7:e1002141. DOI:10.1371/journal.pgen.1002141. [PMC free article] [PubMed]
96. National Geographic ‘Genographic’ Project. (cited 16 July 2011). Available from https://genographic.nationalgeographic.com/genographic/index.html .
97. Genome Wowser By The Children's Hospital of Philadelphia. (cited 16 July 2011). Available from http://itunes.apple.com/us/app/genome-wowser/id437044318?mt=8 .
98. Frueh F.W., Greely H.T., Green R.C., Hogarth S., Siegel S. The future of direct-to-consumer clinical genetic tests. Nat. Rev. Genet. 12. 2011:511–515. doi:10.1038/nrg3026. [PMC free article] [PubMed]
99. Testing times for gene test regulators. Nat. Biotechnol. 2011;29:90. doi:10.1038/nbt.1787. [PubMed]
100. Walt D.R., Kuhlik A., Epstein S.K., Demmer L.A., Knight M., Chelmow D., Rosenblatt M., Bianchi D.W. Lessons learned from the introduction of personalized genotyping into a medical school curriculum. Genet. Med. 2011;13:63–66. doi:10.1097/GIM.0b013e3181f872ac. [PubMed]
101. Howard H.C., Avard D., Borry P. Are the kids really all right? Eur. J. Hum. Genet. 2011 DOI:10.1038/ejhg.2011.94. [PMC free article] [PubMed]
102. Thelin T., Sveger T., McNeil T.F. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD) Acta Paediatr. 1996;85:1207–1212. doi:10.1111/j.1651-2227.1996.tb18230.x. [PubMed]
103. Tercyak K.P., Hensley Alford S., Emmons K.M., Lipkus I.M., Wilfond B.S., McBride C.M. Parents’ attitudes toward pediatric genetic testing for common disease risk. Pediatrics. 2011;127:e1288–e1295. doi:10.1542/peds.2010-0938. [PMC free article] [PubMed]
104. Goetz T. Harnessing the Power of Feedback Loops. Wired; 2011.
105. Topol E.J. Transforming medicine via digital innovation. Sci. Transl. Med. 2010;2 16cm14. [PMC free article] [PubMed]
106. KnomeATLAS: our service for private clients & their families. (cited 6 July 2011). Available from http://www.knome.com/?page_id=1010 .
107. DNA Day: Meet the Osbournes’ geneticist. CNN Health-The Chart; 2011. (cited 15 May 2011). Available from http://thechart.blogs.cnn.com/2011/04/15/dna-day-the-osbournes-geneticist/
108. Worthey E.A., Mayer A.N., Syverson G.D., Helbling D., Bonacci B.B., Decker B., Serpe J.M., Dasu T., Tschannen M.R., Veith R.L., et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 2011;13:255–262. doi:10.1097/GIM.0b013e3182088158. [PubMed]
109. Bainbridge M.N., Wiszniewski W., Murdock D.R., Friedman J., Gonzaga-Jauregui C., Newsham I., Reid J.G., Fink J.K., Morgan M.B., Gingras M.C., et al. Whole-genome sequencing for optimized patient management. Sci. Transl. Med. 2011;3:87re83. [PMC free article] [PubMed]
110. Welch J.S., Westervelt P., Ding L., Larson D.E., Klco J.M., Kulkarni S., Wallis J., Chen K., Payton J.E., Fulton R.S., et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011;305:1577–1584. doi:10.1001/jama.2011.497. [PMC free article] [PubMed]
111. Lynch J., Parrott A., Hopkin R.J., Myers M. Media Coverage of Direct-to-Consumer Genetic Testing. J. Genet. Couns. 2011 DOI:10.1007/s10897-011-9374-9. [PubMed]
112. Sweeny K., Legg A.M. Predictors of interest in direct-to-consumer genetic testing. Psychol. Health. 2011:1–14. DOI:10.1080/08870446.2010.514607. [PubMed]
113. Leighton J.W., Valverde K., Bernhardt B.A. The general public's understanding and perception of direct-to-consumer genetic test results. Public Health Genomics. 2011 DOI:10.1159/000327159. [PubMed]
Articles from Human Molecular Genetics are provided here courtesy of
Oxford University Press